Premium
VIP Decreases TLR4 Expression Induced by LPS and TNF‐α Treatment in Human Synovial Fibroblasts
Author(s) -
JUARRANZ Y.,
GUTIÉRREZCAÑAS I.,
ARRANZ A.,
MARTÍNEZ C.,
ABAD C.,
LECETA J.,
PABLOS J.L.,
GOMARIZ R.P.
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1317.045
Subject(s) - tlr4 , tumor necrosis factor alpha , chemistry , synovial fluid , cancer research , inflammation , medicine , endocrinology , microbiology and biotechnology , pathology , biology , alternative medicine , osteoarthritis
It has been demonstrated that VIP produces beneficial effects both in a murine model of rheumatoid arthritis and in human rheumatoid synovial fibroblasts through the modulation of proinflammatory mediators. Toll‐like receptors (TLRs) play a key role in the immediate recognition of microbial surface components by immune cells prior to the development of adaptative microbe‐specific immune responses. In this study, we demonstrate that VIP decreases lipopolysaccharide (LPS) and TNF‐α‐induced expression of TLR4 and its correlation with the production of CCL2 and CXCL8 chemokines in human synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Our results add a new step for the use of VIP, as a promising candidate, for the treatment of rheumatoid arthritis.